Drug intelligence / Profile preview

COMPOUND 9 (Curadev)

Development stage: Preclinical
Lead developer: Curadev Therapeutics
Modality: Small Molecules
Administration: Intraarticular

Overview

COMPOUND 9 is a small-molecule dual inhibitor of CDC2-like kinases (CLK) and dual-specificity tyrosine-regulated kinases (DYRK) being developed by Curadev Pharma for the treatment of osteoarthritis. The drug is designed to modulate disease-relevant signaling pathways to address the underlying pathology of the disease rather than merely managing symptoms. It is intended for intra-articular administration directly into the affected joint. Curadev has nominated the compound as a candidate for US FDA Investigational New Drug (IND) filing, placing it in the preclinical stage of development.

Targets

DYRK (Dual-specificity tyrosine-phosphorylation-regulated kinase family)CLK (CDC-like kinase family)

Beyond the preview

Go deeper on COMPOUND 9 (Curadev).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on COMPOUND 9 (Curadev).

Explore the full profile